John Desjardins

534 total citations
13 papers, 304 citations indexed

About

John Desjardins is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, John Desjardins has authored 13 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Organic Chemistry. Recurrent topics in John Desjardins's work include Pharmacogenetics and Drug Metabolism (3 papers), Drug Transport and Resistance Mechanisms (2 papers) and Cancer therapeutics and mechanisms (2 papers). John Desjardins is often cited by papers focused on Pharmacogenetics and Drug Metabolism (3 papers), Drug Transport and Resistance Mechanisms (2 papers) and Cancer therapeutics and mechanisms (2 papers). John Desjardins collaborates with scholars based in United States and United Kingdom. John Desjardins's co-authors include Patrick L. Iversen, Frank C. Richardson, Robert H. Heflich, Thomas J. Bucci, Vasily N. Dobrovolsky, Eric Brown, Dennis J. Meyer, David L. Emerson, Marta Hamilton and Blake Tomkinson and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research and Cancer Letters.

In The Last Decade

John Desjardins

13 papers receiving 287 citations

Peers

John Desjardins
Valérie Boutet France
Hamed Gilzad Kohan United States
Isabel Huber‐Ruano Spain
Ram P. Tiwari India
Xiaoyan Xu China
Marco Brughera Italy
Xiaochen Chen China
J. Yates United Kingdom
Rashmi Rana India
Deanna J. Brackman United States
Valérie Boutet France
John Desjardins
Citations per year, relative to John Desjardins John Desjardins (= 1×) peers Valérie Boutet

Countries citing papers authored by John Desjardins

Since Specialization
Citations

This map shows the geographic impact of John Desjardins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Desjardins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Desjardins more than expected).

Fields of papers citing papers by John Desjardins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Desjardins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Desjardins. The network helps show where John Desjardins may publish in the future.

Co-authorship network of co-authors of John Desjardins

This figure shows the co-authorship network connecting the top 25 collaborators of John Desjardins. A scholar is included among the top collaborators of John Desjardins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Desjardins. John Desjardins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
Desjardins, John, et al.. (2003). Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Research. 58(3). 217–225. 48 indexed citations
4.
Dobrovolsky, Vasily N., Thomas J. Bucci, Robert H. Heflich, John Desjardins, & Frank C. Richardson. (2003). Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Molecular Genetics and Metabolism. 78(1). 1–10. 46 indexed citations
5.
Desjardins, John, David L. Emerson, Blake Tomkinson, et al.. (2001). Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anti-Cancer Drugs. 12(3). 235–245. 15 indexed citations
6.
Emerson, David L., Raymond A. Bendele, Eric Brown, et al.. (2000). Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.. PubMed. 6(7). 2903–12. 51 indexed citations
7.
Arora, Vikram, et al.. (1998). In Vivo Properties of an In Situ Forming Gel for Parenteral Delivery of Macromolecular Drugs. Pharmaceutical Research. 15(8). 1189–1195. 15 indexed citations
8.
Desjardins, John, Shannon E. Beard, John Mapoles, Pauline Gee, & John A. Thompson. (1998). Transcriptional activity of quinone methides derived from the tumor promoter butylated hydroxytoluene in HepG2 cells. Cancer Letters. 131(2). 201–207. 10 indexed citations
9.
Porter, Thomas R., Shouping Li, Karen Kilzer, John Desjardins, & Patrick L. Iversen. (1997). Enhanced delivery and effectiveness of antisense oligonucleotides when bound to intravenous perfluorocarbon-filled microbubbles: Effect of ultrasound and therapeutic implications. 10(4). 5 indexed citations
10.
Desjardins, John, Brian S. Sproat, Barbro Beijer, et al.. (1996). Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.. Journal of Pharmacology and Experimental Therapeutics. 278(3). 1419–1427. 23 indexed citations
11.
Desjardins, John, John E. Mata, Tom Brown, et al.. (1995). Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Modulate CYP2B1 ExpressionIn Vivo. Journal of drug targeting. 2(6). 477–485. 25 indexed citations
12.
Tracewell, William, John Desjardins, & Patrick L. Iversen. (1995). In Vivo Modulation of the Rat Cytochrome P450 1A1 by Double-Stranded Phosphorothioate Oligodeoxynucleotides. Toxicology and Applied Pharmacology. 135(2). 179–184. 3 indexed citations
13.
Desjardins, John & Patrick L. Iversen. (1995). Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo.. Journal of Pharmacology and Experimental Therapeutics. 275(3). 1608–1613. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valérie Boutet Breakdown of academic impact, for papers by Hamed Gilzad Kohan Breakdown of academic impact, for papers by Isabel Huber‐Ruano Breakdown of academic impact, for papers by Ram P. Tiwari Breakdown of academic impact, for papers by Xiaoyan Xu Breakdown of academic impact, for papers by Marco Brughera Breakdown of academic impact, for papers by Xiaochen Chen Breakdown of academic impact, for papers by J. Yates Breakdown of academic impact, for papers by Rashmi Rana Breakdown of academic impact, for papers by Deanna J. Brackman
Rankless by CCL
2026